Chief Medical Officer · Spero Therapeutics, Inc. (SPRO)

David Melnick

A named executive officer of Spero Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$999,913

Salary $411,450Stock awards $0

FY2019: $936,288

2nd of 3 named executive officers at Spero Therapeutics by FY2020 total.

3 named officers on file for Spero Therapeutics, FY2020

David Melnick’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spero Therapeutics’s whole pay program stands against its peers

  • Spero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 6, 2021 (DEF 14A).

Free

Get David Melnick’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

David Melnick compensation by year

Spero Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Spero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020
Salary$375,680$389,167$411,450
Bonus$10,000$0$0
Stock awards$0$118,493$0
Option awards$1,082,146$271,837$352,600
Non-equity incentive$146,300$156,000$229,548
Pension and deferred compensation$0$0$0
All other$20,235$792$6,315
Total$1,634,361$936,288$999,913

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spero Therapeutics, Inc. DEF 14A filed July 6, 2021, accession 0001193125-21-208448, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Spero Therapeutics, Inc. filed document, accession 0001193125-21-208448. Every figure is read from that document and cited to the page and table it appears in. Filed July 6, 2021.

$1.6M
$936K
$1000K
FY18
FY19
FY20
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
PSU6,937$88,863—
Option33,854—$6.26
Option11,890—$12.81
Option36,562—$12.14
Option55,000—$9.34

Per the Outstanding Equity Awards at Fiscal Year-End table in Spero Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Spero Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Ankit MahadeviaChief Executive Officer$2,120,788
David Melnick · this pageChief Medical Officer$999,913
Christina LarkinChief Operating Officer$991,962

The full Spero Therapeutics compensation record

free company brief

This page is one person within Spero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Melnick's compensation dossier · One-time report. No refunds.